1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Integration Plan being discussed at HQ

Discussion in 'Amylin' started by Anonymous, Jun 1, 2012 at 10:49 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

     

  2. Anonymous

    Anonymous Guest

    I'm sorry but you are a pathetic piece of shit... You know nothing and are nothing and I hope you are let go by BMS
     
  3. Anonymous

    Anonymous Guest

    This thread is true
     
  4. Anonymous

    Anonymous Guest

    Dont anybody kid themselves. The management positions will all belong to current BMS managers.

    Amylin was bought. They dont get to decide/choose. The company that did the buying calls all the shots. That's the way it always is in any merger/aquisition anywhere.
     
  5. Anonymous

    Anonymous Guest

    Let's just get this crap over. Jake get up there and say nothing of importance blah blah blah. BMS will say we are happy to have this shit company, and keep selling and running the race.

    Sales force will say thank you for nothing and bend over and bite to towel again.
     
  6. Anonymous

    Anonymous Guest

    If you dont like it go to another company!!! Be glad you have a job or maybe you were one of the many that got let go because your number SUCK!!!!!!!!!!!!!!!